department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

HYDROCORTISONE · pharmadog

pharmadog
drugs
HYDROCORTISONE

drug

patient view →

ET-800

Marketedupdated 2mo ago

by $ETON Eton Pharmaceuticals, Inc.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 35 approved and 37 investigational indications.

indications

investigational

Multiple SclerosisIBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma

all catalysts(3)

approval · 3

News(0)

no news has mentioned this drug yet

brand

HYDROCORTISONE

generic

hydrocortisone

MOA

Glucocorticoid receptor agonist

indication

Adrenal Insufficiency

phase

marketed

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE (HYDROCORTISONE) — FDA approval

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE (HYDROCORTISONE) — FDA approval

HYDROCORTISONE — FDA approval

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 19, 2032

~6.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

Feb 23, 2043formulationUS 11904046
Feb 23, 2043method-of-use (U-4215)US 12133914
May 12, 2034formulationUS 9649280
May 12, 2034formulationUS 9649280
May 12, 2034formulationUS 9649280
May 12, 2034formulationUS 9649280
Jan 10, 2033method-of-use (U-3075)US 9675559
Jan 10, 2033method-of-use (U-3075)US 9675559
Jan 10, 2033method-of-use (U-3075)US 9675559
Jan 10, 2033method-of-use (U-3075)US 9675559
Nov 19, 2032method-of-use (U-3075)US 9717740
Nov 19, 2032method-of-use (U-3075)US 9717740
Nov 19, 2032method-of-use (U-3075)US 9717740
Nov 19, 2032method-of-use (U-3075)US 9717740

Data sources

openFDA · ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$AMRX16.92-1.34%

$AMRX16.92-1.34%

🐶 often sniffed alongside

top 8

drugNEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE16 co-mentions · 6 sources
tagApproval14 co-mentions · 5 sources
drugHYDROCORTISONE12 co-mentions · 6 sources
drugpolymyxin B4 co-mentions · 2 sources
drugCIPROFLOXACIN HYDROCHLORIDE2 co-mentions · 1 sources
drugciprofloxacin2 co-mentions · 1 sources
drugciprofloxacin hydrochloride ER2 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources

Trials studying ET-800

phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)recruitingn=1,314
phase1A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapyrecruitingn=36
phase3Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)recruitingn=1,310
phase1A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)completedn=14
phase1Venetoclax Basket Trial for High Risk Hematologic Malignanciesrecruitingn=30
phase1Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)recruitingn=86
phase1A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)active not recruitingn=6
phase2Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)recruitingn=100

more trials →